Diasome Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Diasome General Information

Description

Developer of novel and cell-targeted therapies designed to treat diabetes, obesity, and other metabolic conditions. The company's therapies leverage technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes, enabling patients to get novel proprietary liver-targeted insulins for both Type one and Type two diabetes easily.

Contact Information

Website
www.diasome.com
Formerly Known As
Diasome Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10000 Cedar Avenue
  • Suite 6
  • Cleveland, OH 44106
  • United States
+1 (216)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 10000 Cedar Avenue
  • Suite 6
  • Cleveland, OH 44106
  • United States
+1 (216)

Diasome Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diasome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private Completed Clinical Trials - Phase 2
9. Later Stage VC 14-Aug-2024 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 30-Jun-2023 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 08-Sep-2022 Completed Clinical Trials - Phase 2
6. Secondary Transaction - Private Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B2) 26-Oct-2018 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 05-Jul-2017 Completed Clinical Trials - Phase 1
3. Secondary Transaction - Private Completed Pre-Clinical Trials
2. Later Stage VC (Series B) 10-Apr-2009 $13.2M $16.4M Completed Pre-Clinical Trials
1. Later Stage VC (Series A) $3.2M $3.2M Completed Startup
To view Diasome’s complete valuation and funding history, request access »

Diasome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B-2
Series B-1
Series B 11,382,112 $0.000100 8% $1.23 $1.23 1x $1.23 13.07%
Series A 20,852,974 $0.000100 8% $1.23 $1.23 1x $1.23 23.94%
To view Diasome’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Diasome Patents

Diasome Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026187938-A1 Compositions for delivery of therapeutic drugs and methods using same Pending 04-Mar-2025
WO-2026161629-A1 Compositions and methods for modulating peripheral and hepatic lipid metabolism in hdv-based insulin therapy Pending 24-Jan-2025
WO-2026107515-A1 Incretin hormone compositions and methods using same Pending 18-Nov-2024
US-12758504-B2 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus Active 05-Jan-2018
US-20240108585-A1 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus Active 05-Jan-2018 A61K9/5123
To view Diasome’s complete patent history, request access »

Diasome Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Diasome Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eli Lilly and Company Foundation Limited Partner Minority
T1D Fund Venture Capital Minority
To view Diasome’s complete investors history, request access »

Diasome FAQs

  • When was Diasome founded?

    Diasome was founded in 2004.

  • Where is Diasome headquartered?

    Diasome is headquartered in Cleveland, OH.

  • What is the size of Diasome?

    Diasome has 10 total employees.

  • What industry is Diasome in?

    Diasome’s primary industry is Drug Discovery.

  • Is Diasome a private or public company?

    Diasome is a Private company.

  • What is Diasome’s current revenue?

    The current revenue for Diasome is .

  • How much funding has Diasome raised over time?

    Diasome has raised $89.7M.

  • Who are Diasome’s investors?

    Eli Lilly and Company Foundation and T1D Fund have invested in Diasome.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process